BamSEC and AlphaSense Join Forces
Learn More

AVEO Pharmaceuticals Inc

Formerly NASDAQ: AVEO
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.48
from 10-K 8 pages Revocable Temporary License Agreement This Revocable Temporary License Agreement
12/34/56
EX-10.47
from 10-K 5 pages First Amendment to Sublease Agreement 30 Winter Street Boston, Massachusetts
12/34/56
EX-10.39
from 10-K 68 pages License Agreement by and Between Eusa Pharma (Uk) Limited and AVEO Pharmaceuticals, Inc Dated: December 18, 2015
12/34/56
EX-10.32
from 10-K 42 pages Agreement
12/34/56
EX-10.24
from 10-K 5 pages Non-Competition and Non-Solicitation Agreement
12/34/56
EX-10.23
from 10-K 12 pages AVEO Pharmaceuticals, Inc. Executive Severance and Change in Control Benefits Plan
12/34/56
EX-10.22
from 10-K 15 pages Severance and Change in Control Agreement . This Severance and Change in Control Agreement (The "Agreement"), Made This
12/34/56
EX-10.21
from 10-K 4 pages November 12, 2021 Compensation: •base Salary. Your Base Salary Will Be at the Annualized Rate of $450,000 Paid Semi-Monthly in Accordance With the Company's Standard Payroll Practices
12/34/56
EX-10.20
from 10-K 13 pages Severance and Change in Control Agreement
12/34/56
EX-10.19
from 10-K 2 pages Material contract
12/34/56
EX-10.2
from 10-Q 53 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions
12/34/56
EX-10.1
from 8-K 12 pages Transition, Separation, and Release of Claims Agreement
12/34/56
EX-10.3
from 10-Q 2 pages Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement
12/34/56
EX-10.2
from 10-Q 39 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions
12/34/56
EX-10.28
from 10-K 4 pages Amendment No. 1 to Option and License Agreement
12/34/56
EX-10.27
from 10-K 85 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Option and License Agreement by and Between AVEO Pharmaceuticals, Inc. and Biogen Idec International Gmbh Option and License Agreement
12/34/56
EX-10.1
from 8-K 8 pages Separation and Release of Claims Agreement
12/34/56
EX-10.2
from 10-Q 16 pages Sublease Agreement
12/34/56
EX-10.17
from 10-K 15 pages Severance and Change in Control Agreement
12/34/56
EX-10.16
from 10-K 3 pages It Is With Great Pleasure That We Extend You This Offer of Employment to Join AVEO Pharmaceuticals. the Following Letter Sets Forth the Proposed Terms and Conditions of Your Offer of EMPLOYMENT.POSITION. Your Position Will Be Chief Financial Officer, and You Will Be Designated a “Section 16 Officer” (With the Meaning of Rule 16a-1(f) Under the Securities Exchange Act of 1934). if You Accept This Offer, Your Employment With the Company Shall Commence on a Mutually Agreed Upon Date. Compensation: • Base Salary. Your Annual Salary Will Be at the Annualized Rate of $340,000 Paid Semi-Monthly
12/34/56